Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Identification of Cystic Fibrosis Variants by Polymerase Chain Reaction/Oligonucleotide Ligation Assay

Identification of Cystic Fibrosis Variants by Polymerase Chain Reaction/Oligonucleotide Ligation... The purpose of this work is to define rare variants of cystic fibrosis (CF) that are potential sources of error and can confound molecular genetic testing methods. We performed routine, clinical CF mutation screening using a laboratory-developed test and the oligonucleotide ligation assay reagents from Abbott/Celera. In this report, we describe 11 unique allele drop outs 3849 + 10kb C>T (NM_000492.2:c.3718-2477C>T), V520F (c.1558G>T), 1078delT (c.948delT), A455E (c.1364C>A), R347P (c.1040G>C), 2184delA (c.2052delA), W1282X (c.3846G>A), R117H (c.350G>A), G85E (c.254G>A), 621 + 1G>T (c.489 + 1G>T), and 2789 + 5G>A (c.2657 + 5G>A) observed with this platform. The allele drop outs account for less than 0.01% of all results reported in our laboratory. Both the recognition and enumeration of such variants along with clinical information in CF testing is valuable in avoiding false-positive and false-negative results. Related Article Cystic Fibrosis Testing Comes of Age Wayne W. Grody J. Mol. Diagn. 2009 11: 173-175. Abstract Full Text PDF http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Molecular Diagnostics American Society for Investigative Pathology

Identification of Cystic Fibrosis Variants by Polymerase Chain Reaction/Oligonucleotide Ligation Assay

Identification of Cystic Fibrosis Variants by Polymerase Chain Reaction/Oligonucleotide Ligation Assay

Journal of Molecular Diagnostics , Volume 11 (3): 211 – May 1, 2009

Abstract

The purpose of this work is to define rare variants of cystic fibrosis (CF) that are potential sources of error and can confound molecular genetic testing methods. We performed routine, clinical CF mutation screening using a laboratory-developed test and the oligonucleotide ligation assay reagents from Abbott/Celera. In this report, we describe 11 unique allele drop outs 3849 + 10kb C>T (NM_000492.2:c.3718-2477C>T), V520F (c.1558G>T), 1078delT (c.948delT), A455E (c.1364C>A), R347P (c.1040G>C), 2184delA (c.2052delA), W1282X (c.3846G>A), R117H (c.350G>A), G85E (c.254G>A), 621 + 1G>T (c.489 + 1G>T), and 2789 + 5G>A (c.2657 + 5G>A) observed with this platform. The allele drop outs account for less than 0.01% of all results reported in our laboratory. Both the recognition and enumeration of such variants along with clinical information in CF testing is valuable in avoiding false-positive and false-negative results. Related Article Cystic Fibrosis Testing Comes of Age Wayne W. Grody J. Mol. Diagn. 2009 11: 173-175. Abstract Full Text PDF

Loading next page...
 
/lp/american-society-for-investigative-pathology/identification-of-cystic-fibrosis-variants-by-polymerase-chain-QGr0jJ1RSS

References (15)

Publisher
American Society for Investigative Pathology
Copyright
Copyright © 2009 by the American Society for Investigative Pathology and the Association for Molecular Pathology.
ISSN
1525-1578
eISSN
1525-1578
DOI
10.2353/jmoldx.2009.080106
pmid
19324992
Publisher site
See Article on Publisher Site

Abstract

The purpose of this work is to define rare variants of cystic fibrosis (CF) that are potential sources of error and can confound molecular genetic testing methods. We performed routine, clinical CF mutation screening using a laboratory-developed test and the oligonucleotide ligation assay reagents from Abbott/Celera. In this report, we describe 11 unique allele drop outs 3849 + 10kb C>T (NM_000492.2:c.3718-2477C>T), V520F (c.1558G>T), 1078delT (c.948delT), A455E (c.1364C>A), R347P (c.1040G>C), 2184delA (c.2052delA), W1282X (c.3846G>A), R117H (c.350G>A), G85E (c.254G>A), 621 + 1G>T (c.489 + 1G>T), and 2789 + 5G>A (c.2657 + 5G>A) observed with this platform. The allele drop outs account for less than 0.01% of all results reported in our laboratory. Both the recognition and enumeration of such variants along with clinical information in CF testing is valuable in avoiding false-positive and false-negative results. Related Article Cystic Fibrosis Testing Comes of Age Wayne W. Grody J. Mol. Diagn. 2009 11: 173-175. Abstract Full Text PDF

Journal

Journal of Molecular DiagnosticsAmerican Society for Investigative Pathology

Published: May 1, 2009

There are no references for this article.